Search

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more

European Hematology Curriculum

Harmonization of hematology knowledge is part of EHA’s mission. The first step in harmonizing hematology training is to stipulate the required fields of knowledge, each with its recommended level of competence.

Read more

EHA Statement on the Erasmus MC Attack

EHA is deeply saddened and appalled by the news of the twin shootings in Rotterdam, the Netherlands. We condemn these senseless acts of violence in the strongest possible terms.

Read more

Sponsor and Fundraising Committee

Current committee members
Martin Dreyling, Germany (Chair (EHA Board))
Antonio Pierini, Italy (Vice Chair (non-Board member))
Igor Aurer, Croatia (Representative, SWG Committee)
Mariane de Montalembert, France (Councilor)
Konstanze Döhner, Germany (EHA Board)
Kirsten Gronbaek, Denmark (EHA Board)
Frank Leebeek, The Netherlands (Councilor)
David Rees, United Kingdom (Representative, Education…

Read more

Reduction of chemotherapy and PET-guided radiotherapy in advanced-stage Hodgkin lymphoma: the GHSG HD15 trial

Using the multi-agent chemotherapy regimen BEACOPP the GHSG demonstrated significantly better tumor control and overall survival compared to previously used regimens. In addition, the need for radiotherapy in patients with advanced stage Hodgkin lymphoma has been unclear.

Read more